GeoVax Labs, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. The filing also reports unaudited quarterly results; fourth quarter 2015 ended December 31. GeoVax is a clinical-stage vaccine developer with no product sales or approved products. Revenue consisted of NIH grant income.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Grant revenue | $428,081 | $882,956 | Down 52% |
| Research and development expense | $1,693,102 | $1,812,969 | Down 7% |
| General and administrative expense | $1,429,731 | $1,807,605 | Down 21% |
| Net loss | $2,689,287 | $2,733,555 | Loss narrowed 2% |
| Net loss per share | $0.08 | $0.10 | — |
| Net cash used in operating activities | $2,705,263 | $2,250,107 | Cash use increased 20% |
Fourth-quarter 2015 grant revenue was $160,053 and net loss was $692,731, versus $223,089 and $923,585, respectively, in fourth-quarter 2014. Profit margins are not meaningful because the company had no product revenue and grant revenue approximately tracks qualifying costs.
At year-end, cash and cash equivalents were $1,060,348, working capital was $1,109,985, total assets were $1,331,593, and stockholders’ equity was $1,204,603. The company reported no committed lines of credit or long-term debt. It raised approximately $2.68 million net from Series C preferred stock in February 2015; net financing cash flow for 2015 was $2,679,810. Capital expenditures were $15,850.
Material changes and business developments
- Grant revenue fell substantially as grant-supported activity and spending declined. R&D expense also decreased, while G&A expense fell partly because stock-based compensation declined to $67,905 from $479,103 in 2014.
- Operating cash use increased despite a slightly smaller net loss. Cash at year-end was nearly unchanged from 2014, with financing proceeds offsetting operating cash consumption.
- The clade B preventive HIV vaccine had completed Phase 2a testing. GeoVax expected an NIH-funded Phase 1 trial with a protein boost to begin in mid-2016 and was also seeking support for a Phase 2b efficacy trial.
- Development expanded to hemorrhagic-fever vaccines, cancer immunotherapy, and Zika. The company planned additional non-human-primate Ebola challenge studies in 2016 and aimed to begin human trials in 2017; initial Zika and cancer proof-of-concept animal studies were planned for 2016.
Outlook, risks, contingencies, and unusual items
- Going concern and funding: The auditor highlighted substantial doubt about GeoVax’s ability to continue as a going concern. The financial-statement note says existing cash and grant commitments should fund planned operations through the second quarter of 2016, while MD&A says into the third quarter. Management expected to seek grants, clinical-trial support, warrant exercises, and/or additional securities financing; funding was not assured.
- Development and regulatory risk: All candidates remained unapproved and experimental. Clinical outcomes, trial timing, regulatory approval, manufacturing, and future commercial revenue are uncertain. The company relies on NIH/HVTN support and third-party manufacturers and service providers.
- Potential dilution: At December 31, 2015, approximately 90.3 million common-share equivalents were excluded from diluted loss per share as anti-dilutive, compared with 6.6 million a year earlier. These included warrants and convertible preferred stock. Series C conversion terms and warrants had price-adjustment provisions. Subsequent to year-end, warrant amendments generated $238,198 net proceeds and a $469,800 non-cash expense; 1.4 million common shares were issued upon Series C conversions during January and February 2016.
- Other obligations and risks: The company disclosed $222,000 of near-term lease and firm purchase commitments, plus contingent Emory University milestones of approximately $3.5 million and future royalties if products are commercialized. It had no material legal proceedings. It reported effective disclosure controls and internal control over financial reporting.
- Unusual item: The company’s 2015 Series C financing included warrants and anti-dilution features; warrant exercise prices and preferred conversion prices had been adjusted. These terms can affect proceeds, share count, and existing shareholders’ ownership.
Important facts for investors to verify
- Reconcile the stated cash runway: the filing gives both second-quarter and third-quarter 2016 estimates, and assess subsequent financing and cash burn.
- Review the auditor’s going-concern emphasis and whether GeoVax obtained sufficient funding after the filing date.
- Check the status, funding, and timelines for the planned HIV, hemorrhagic-fever, Zika, and cancer studies; stated dates are forward-looking targets.
- Quantify potential dilution from warrants, preferred-stock conversions, and anti-dilution provisions, including subsequent exercises and conversions.
- Confirm that NIH grant support continues and distinguish grant revenue from commercial revenue; the company had no product sales.